
News|Articles|January 1, 2012
FDA Pipeline Preview, January 2012 (Alexza Pharmaceuticals, Pfizer, Celladon, Vertex, Avedro)
Recent FDA action (through December 2011) related to staccato loxapine, axitinib, mydicar, kalydeco, riboflavin ophthalmic solution, minocycline hydrochloride
Advertisement
Recommendations for approval
Fast-track designation
Priority review
• First-time generic approval
MInocycline hydrocholride extended-release tablets in 45-mg, 55-mg, 90-mg, and 135-mg strengths (equiv to Solodyn)
LUPIN PHARMACEUTICALS
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare’s first-year payments for social needs showed high use by primary care but many claims were denied
2
House passes funding bill that includes PBM reform
3
See which Minnesota healthcare CEOs signed letter calling for 'immediate deescalation of tensions' following shooting of Alex Pretti
4
Do you know what’s in your contracts?
5




























